Actively Recruiting
Autonomic Reactivity and Personalized Neurostimulation
Led by Medical College of Wisconsin · Updated on 2026-02-13
120
Participants Needed
1
Research Sites
227 weeks
Total Duration
On this page
Sponsors
M
Medical College of Wisconsin
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology. Many patients manifest comorbidities suggesting an underlying autonomic nervous system (ANS) dysregulation (palpitations, dizziness, cognitive dysfunction). Unfortunately, due to common features of anxiety and visceral hyperreactivity and lack of obvious pathology, children with DGBI are frequently diagnosed with psychosomatic or 'benign, functional disorders' and treated with empiric antidepressants despite lack of scientific support and risks of serious side effects. Little is known about the underlying brain-gut mechanisms linking these comorbidities. A lack of targeted treatment options naturally follows the paucity of mechanistic data. A dysregulated ANS response circuit via brainstem nuclei is linked to visceral hypersensitivity. As the team's prior research has shown, ANS regulation can be non-invasively measured via several validated indices of cardiac vagal tone. Using the novel vagal efficiency (VE) metric, the investigators have demonstrated inefficient vagal regulation in cyclic vomiting syndrome and pain-related DGBI and that low VE predicts response to non-invasive, auricular percutaneous electrical nerve field stimulation (PENFS) therapy. PENFS targets brainstem vagal afferent pathways and, along with brain-gut interventions such as hypnotherapy, are the only therapies currently proven effective for pediatric DGBI. Individualizing neurostimulation based on sensory thresholds while assessing dynamic ANS reactivity offers a path towards personalized medicine using the most effective therapies to date. This proposal will test the feasibility of an ANS tracking software in assessing real-time, autonomic regulation and providing individualized neurostimulation in children with nausea/vomiting and ANS imbalance.
CONDITIONS
Official Title
Autonomic Reactivity and Personalized Neurostimulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 11 to 18 years
- English speaking
- Meets Rome IV criteria for cyclic vomiting syndrome or functional dyspepsia
- Willingness to participate and provide consent/assent
- Chronic symptoms of autonomic dysfunction for at least 3 months, including dizziness, syncope, palpitations, fatigue, sleep disturbance, thermoregulatory issues, or cognitive impairment when upright
You will not qualify if you...
- Presence of organic disease explaining symptoms
- Need for parenteral nutrition
- Developmental delays preventing accurate symptom reporting
- Severe skin condition or active infection of the external or middle ear
- Having an implanted electrical device
- Severe uncontrolled mental health disorders (schizophrenia, bipolar disorder, severe depression, PTSD) or psychotic features affecting symptom report or response to hypnosis therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53005
Actively Recruiting
Research Team
E
Elaina Schueler, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here